glp 1 inhibitors What is GLP-1 and Its Receptor Agonists? How GLP-1 Receptor Agonists Evolved
Description
PF-07976016 - oral GIPR antagonist Phase 2
Reduced risk of side effects
other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome
hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)
Thats why the FDA gives it a boxed warning
GLP-1 drugs, which include Ozempic and Wegovy, have becomeone of the most closely watched experimental approachesfor slowing Alzheimers a disease with few treatment options.
